14-day Premium Trial Subscription Sign Up For FreeGet Free

Weaker Stock
Today AEZS ranks #17447 as sell candidate. Get a Free Stock at Robinhood
Stronger Stock

AEterna Zentaris Inc. Stock Forecast NASDAQ:AEZS

$0.34 (-0.97%)

Volume: 857k

Closed: Jan 19, 2022

Hollow Logo Score: -5.109

AEterna Zentaris Inc. Stock Forecast

$0.34 (-0.97%)

Volume: 857k

Closed: Jan 19, 2022

Score Hollow Logo -5.109

AEterna Zentaris Inc. Company Profile

315 Sigma Drive

Summerville SC 29483



Industry: Biotechnology

Sector: Healthcare

AEterna Zentaris Inc.


Aeterna Zentaris Inc., a specialty biopharmaceutical company, engages in developing and commercializing novel treatments in oncology, endocrinology, and women's health. The company’s product pipeline includes Zoptrex, which is in Phase III clinical study zoptarelin doxorubicin in endometrial cancer (ZoptEC) of the compound in women with advanced, recurrent, or metastatic endometrial cancer, as well as completed Phase II clinical trial for the treatment of ovarian and prostate cancer; and MACRILEN, which is in Phase III trial for use in the diagnosis of adult growth hormone deficiency. It is also developing two oncology compounds, including an Erk inhibitor and luteinizing hormone-releasing hormone-disorazol Z product candidates, which are in pre-clinical development; and AEZS-120 for the treatment of prostate cancer. Aeterna Zentaris Inc. was founded in 1991 and is headquartered in Summerville, South Carolina.

Top Fintech Company

StockInvest.us featured in The Global Fintech Index 2020 as the top Fintech company of the country.

Full report by FINDEXABLE